Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease

Open access
Han, Yaling, Zhu, Guoying, Han, Lixian, Hou, Fengxia, Huang, Weijian, Liu, Huiliang, Gan, Jihong, Jiang, Tiemin, Li, Xiaoyan, Wang, Wei, Ding, Shifang, Jia, Shaobin, Shen, Weifeng, Wang, Dongmei, Sun, Ling, Qiu, Jian, Wang, Xiaozeng, Li, Yi, Deng, Jie, Li, Jing, Xu, Kai, Xu, Bo, Mehran, Roxana, Huo, Yong·2014·Journal of the American College of Cardiology

Abstract

OBJECTIVES: This study sought to evaluate the safety and efficacy of rosuvastatin in preventing contrast-induced acute kidney injury (CI-AKI) in patients with diabetes mellitus (DM) and chronic kidney disease (CKD). BACKGROUND: CI-AKI is an important complication after contrast medium injection. While small studies have shown positive results with statin therapy, the role of statin therapy in prevention of CI-AKI remains unknown. METHODS: We randomized 2,998 patients with type 2 DM and concomitant CKD who were undergoing coronary/peripheral arterial angiography with or without percutaneous intervention to receive rosuvastatin, 10 mg/day (n = 1,498), for 5 days (2 days before, and 3 days after procedure) or standard-of-care (n = 1,500). Patients' renal function was assessed at baseline, 48 h, and 72 h after exposure to contrast medium. The primary endpoint of the study was the development of CI-AKI, which was defined as an increase in serum creatinine concentration ≥0.5 mg/dl (44.2 μmol/l) or 0.25% above baseline at 72 h after exposure to contrast medium. RESULTS: Patients randomized to the rosuvastatin group had a significantly lower incidence of CI-AKI than controls (2.3% vs. 3.9%, respectively; p = 0.01). During 30 days' follow-up, the rate of worsening heart failure was significantly lower in the patients treated with rosuvastatin than that in the control group (2.6% vs. 4.3%, respectively; p = 0.02). CONCLUSIONS: Rosuvastatin significantly reduced the risk of CI-AKI in patients with DM and CKD undergoing arterial contrast medium injection. (Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes [TRACK-D]; NCT00786136).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.09.017

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 217

Metadata

Authors
Han, Y., Zhu, G., Han, L., Hou, F., Huang, W., Liu, H., Gan, J., Jiang, T., Li, X., Wang, W., Ding, S., Jia, S., Shen, W., Wang, D., Sun, L., Qiu, J., Wang, X., Li, Y., Deng, J., Li, J., Xu, K., Xu, B., Mehran, R., & Huo, Y.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2014-01
Volume
63
Issue
1
Pages
62-70
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2020675649
Cited by
217
References
4
FWCI
20.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease. https://app.cochat.ai/papers/10.1016/j.jacc.2013.09.017
The paper
Han, Y., Zhu, G., Han, L., Hou, F., Huang, W., Liu, H., Gan, J., Jiang, T., Li, X., Wang, W., Ding, S., Jia, S., Shen, W., Wang, D., Sun, L., Qiu, J., Wang, X., Li, Y., Deng, J., . . . Huo, Y. (2014). Short-Term Rosuvastatin Therapy for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2013.09.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.